Trials / Unknown
UnknownNCT05525884
Mechanism of Serum PRL in the Development of MAFLD
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Shen Qu · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently. However, the relationship between serum PRL and MAFLD among diabetic patients is unclear. The investigators aimed to explore the association between serum PRL and the risk of MAFLD in patients with type 2 diabetes (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | non-invasive method, Fibroscan | Liver Ultrasound and transient elastography (FibroScan®) |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-01-31
- First posted
- 2022-09-02
- Last updated
- 2022-09-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05525884. Inclusion in this directory is not an endorsement.